Non‐clinical safety and biodistribution of AS03‐adjuvanted inactivated pandemic influenza vaccines
Identifieur interne : 002194 ( Istex/Curation ); précédent : 002193; suivant : 002195Non‐clinical safety and biodistribution of AS03‐adjuvanted inactivated pandemic influenza vaccines
Auteurs : Lawrence Segal [Belgique] ; Sandrine Wouters [Belgique] ; Danielle Morelle [Belgique] ; Gaëlle Gautier [France] ; Julien Le Gal [France] ; Thomas Martin [Royaume-Uni] ; Frieke Kuper [Pays-Bas] ; Eric Destexhe [Belgique] ; Arnaud M. Didierlaurent [Belgique] ; Nathalie Garçon [Belgique]Source :
- Journal of Applied Toxicology [ 0260-437X ] ; 2015-12.
Abstract
Pandemic‐influenza vaccines containing split‐inactivated‐virus antigen have been formulated with the immunostimulatory Adjuvant System AS03 to enhance the antigen immunogenicity and reduce antigen content per dose. AS03 is an oil‐in‐water emulsion containing α‐tocopherol, squalene and polysorbate 80. To support the clinical development of AS03‐adjuvanted pandemic‐influenza vaccines, the local and systemic toxicity of test articles containing split‐influenza A(H5N1) and/or AS03 were evaluated after 3–4 intramuscular (i.m.) injections in rabbits. Treatment‐related effects were restricted to mild inflammatory responses and were induced primarily by the test articles containing AS03. The injection‐site inflammation was mild at 3 days, and minimal at 4 weeks after the last injection; and was reflected by signs of activation in the draining lymph nodes and by systemic effects in the blood including a transient increase of neutrophils. In addition, a study in mice explored the biodistribution of A(H5N1) vaccines or AS03 through radiolabelling the antigen or constituents of AS03 prior to injection. In this evaluation, 57–73% of AS03's principal constituents had cleared from the injection site 3 days after injection, and their different clearance kinetics were suggestive of AS03's dissociation. All these AS03 constituents entered into the draining lymph nodes within 30 min after injection. In conclusion, the administration of repeated doses of the H5N1/AS03 vaccine was well tolerated in the rabbit, and was primarily associated with transient mild inflammation at the injection site and draining lymph nodes. The biodistribution kinetics of AS03 constituents in the mouse were consistent with AS03 inducing this pattern of inflammation. Copyright © 2015 John Wiley & Sons, Ltd.
To support the clinical development of candidate AS03‐adjuvanted pandemic‐influenza vaccines, local and systemic toxicity of 3–4 intramuscular (i.m.) injections of AS03, or AS03‐adjuvanted or unadjuvanted split‐A(H5N1) vaccines was evaluated in rabbits. The biodistribution of split‐A(H5N1) vaccines and the constituents of AS03 was explored in mice. All test articles were well tolerated. Treatment‐related effects were primarily associated with AS03 and were indicative of a transient mild local inflammation. The biodistribution kinetics of AS03 constituents were consistent with AS03 inducing this inflammation.
Url:
DOI: 10.1002/jat.3130
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002194
Links to Exploration step
ISTEX:DBE0ACE0CB1C383C471B072CC5D1B71DD762A2FBLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Non‐clinical safety and biodistribution of AS03‐adjuvanted inactivated pandemic influenza vaccines</title><author><name sortKey="Segal, Lawrence" sort="Segal, Lawrence" uniqKey="Segal L" first="Lawrence" last="Segal">Lawrence Segal</name><affiliation wicri:level="1"><mods:affiliation>GSK Vaccines, Rue de l'Institut 89, 1330, Rixensart, Belgium</mods:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>GSK Vaccines, Rue de l'Institut 89, 1330, Rixensart</wicri:regionArea></affiliation><affiliation><mods:affiliation>Correspondence to: to. Lawrence Segal, GSK Vaccines, Rue Fleming 20, 1300 Wavre, Belgium. E‐mail: Arnaud Didierlaurent, GSK Vaccines, Rue de l'Institut 89, 1330 Rixensart, Belgium.E‐mail:</mods:affiliation><wicri:noCountry code="subField">Belgium.E‐mail:</wicri:noCountry></affiliation><affiliation><mods:affiliation>E-mail: lawrence.m.segal@gsk.comarnaud.x.didierlaurent@gsk.com</mods:affiliation><wicri:noCountry code="no comma">E-mail: lawrence.m.segal@gsk.comarnaud.x.didierlaurent@gsk.com</wicri:noCountry></affiliation></author><author><name sortKey="Wouters, Sandrine" sort="Wouters, Sandrine" uniqKey="Wouters S" first="Sandrine" last="Wouters">Sandrine Wouters</name><affiliation wicri:level="1"><mods:affiliation>GSK Vaccines, Rue de l'Institut 89, 1330, Rixensart, Belgium</mods:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>GSK Vaccines, Rue de l'Institut 89, 1330, Rixensart</wicri:regionArea></affiliation></author><author><name sortKey="Morelle, Danielle" sort="Morelle, Danielle" uniqKey="Morelle D" first="Danielle" last="Morelle">Danielle Morelle</name><affiliation wicri:level="1"><mods:affiliation>GSK Vaccines, Rue de l'Institut 89, 1330, Rixensart, Belgium</mods:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>GSK Vaccines, Rue de l'Institut 89, 1330, Rixensart</wicri:regionArea></affiliation></author><author><name sortKey="Gautier, Gaelle" sort="Gautier, Gaelle" uniqKey="Gautier G" first="Gaëlle" last="Gautier">Gaëlle Gautier</name><affiliation wicri:level="1"><mods:affiliation>Chelatec SAS, 1 rue Aronnax, 44821, Saint‐Herblain Cedex, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Chelatec SAS, 1 rue Aronnax, 44821, Saint‐Herblain Cedex</wicri:regionArea></affiliation></author><author><name sortKey="Le Gal, Julien" sort="Le Gal, Julien" uniqKey="Le Gal J" first="Julien" last="Le Gal">Julien Le Gal</name><affiliation wicri:level="1"><mods:affiliation>Chelatec SAS, 1 rue Aronnax, 44821, Saint‐Herblain Cedex, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Chelatec SAS, 1 rue Aronnax, 44821, Saint‐Herblain Cedex</wicri:regionArea></affiliation></author><author><name sortKey="Martin, Thomas" sort="Martin, Thomas" uniqKey="Martin T" first="Thomas" last="Martin">Thomas Martin</name><affiliation wicri:level="2"><mods:affiliation>Covance Laboratories Ltd., Otley Road, HG3 1PY, Harrogate, England</mods:affiliation><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>Covance Laboratories Ltd., Otley Road, HG3 1PY, Harrogate</wicri:cityArea></affiliation></author><author><name sortKey="Kuper, Frieke" sort="Kuper, Frieke" uniqKey="Kuper F" first="Frieke" last="Kuper">Frieke Kuper</name><affiliation wicri:level="1"><mods:affiliation>TNO, Utrechtseweg 48, AJ, NL‐3700, Zeist, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>TNO, Utrechtseweg 48, AJ, NL‐3700, Zeist</wicri:regionArea></affiliation></author><author><name sortKey="Destexhe, Eric" sort="Destexhe, Eric" uniqKey="Destexhe E" first="Eric" last="Destexhe">Eric Destexhe</name><affiliation wicri:level="1"><mods:affiliation>GSK Vaccines, Rue de l'Institut 89, 1330, Rixensart, Belgium</mods:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>GSK Vaccines, Rue de l'Institut 89, 1330, Rixensart</wicri:regionArea></affiliation></author><author><name sortKey="Didierlaurent, Arnaud M" sort="Didierlaurent, Arnaud M" uniqKey="Didierlaurent A" first="Arnaud M." last="Didierlaurent">Arnaud M. Didierlaurent</name><affiliation wicri:level="1"><mods:affiliation>GSK Vaccines, Rue de l'Institut 89, 1330, Rixensart, Belgium</mods:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>GSK Vaccines, Rue de l'Institut 89, 1330, Rixensart</wicri:regionArea></affiliation><affiliation><mods:affiliation>Correspondence to: to. Lawrence Segal, GSK Vaccines, Rue Fleming 20, 1300 Wavre, Belgium. E‐mail: Arnaud Didierlaurent, GSK Vaccines, Rue de l'Institut 89, 1330 Rixensart, Belgium.E‐mail:</mods:affiliation><wicri:noCountry code="subField">Belgium.E‐mail:</wicri:noCountry></affiliation><affiliation><mods:affiliation>E-mail: lawrence.m.segal@gsk.comarnaud.x.didierlaurent@gsk.com</mods:affiliation><wicri:noCountry code="no comma">E-mail: lawrence.m.segal@gsk.comarnaud.x.didierlaurent@gsk.com</wicri:noCountry></affiliation></author><author><name sortKey="Garcon, Nathalie" sort="Garcon, Nathalie" uniqKey="Garcon N" first="Nathalie" last="Garçon">Nathalie Garçon</name><affiliation wicri:level="1"><mods:affiliation>GSK Vaccines, Rue de l'Institut 89, 1330, Rixensart, Belgium</mods:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>GSK Vaccines, Rue de l'Institut 89, 1330, Rixensart</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DBE0ACE0CB1C383C471B072CC5D1B71DD762A2FB</idno><date when="2015" year="2015">2015</date><idno type="doi">10.1002/jat.3130</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-63G3MV8H-1/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002194</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002194</idno><idno type="wicri:Area/Istex/Curation">002194</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Non‐clinical safety and biodistribution of AS03‐adjuvanted inactivated pandemic influenza vaccines</title><author><name sortKey="Segal, Lawrence" sort="Segal, Lawrence" uniqKey="Segal L" first="Lawrence" last="Segal">Lawrence Segal</name><affiliation wicri:level="1"><mods:affiliation>GSK Vaccines, Rue de l'Institut 89, 1330, Rixensart, Belgium</mods:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>GSK Vaccines, Rue de l'Institut 89, 1330, Rixensart</wicri:regionArea></affiliation><affiliation><mods:affiliation>Correspondence to: to. Lawrence Segal, GSK Vaccines, Rue Fleming 20, 1300 Wavre, Belgium. E‐mail: Arnaud Didierlaurent, GSK Vaccines, Rue de l'Institut 89, 1330 Rixensart, Belgium.E‐mail:</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: lawrence.m.segal@gsk.comarnaud.x.didierlaurent@gsk.com</mods:affiliation></affiliation></author><author><name sortKey="Wouters, Sandrine" sort="Wouters, Sandrine" uniqKey="Wouters S" first="Sandrine" last="Wouters">Sandrine Wouters</name><affiliation wicri:level="1"><mods:affiliation>GSK Vaccines, Rue de l'Institut 89, 1330, Rixensart, Belgium</mods:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>GSK Vaccines, Rue de l'Institut 89, 1330, Rixensart</wicri:regionArea></affiliation></author><author><name sortKey="Morelle, Danielle" sort="Morelle, Danielle" uniqKey="Morelle D" first="Danielle" last="Morelle">Danielle Morelle</name><affiliation wicri:level="1"><mods:affiliation>GSK Vaccines, Rue de l'Institut 89, 1330, Rixensart, Belgium</mods:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>GSK Vaccines, Rue de l'Institut 89, 1330, Rixensart</wicri:regionArea></affiliation></author><author><name sortKey="Gautier, Gaelle" sort="Gautier, Gaelle" uniqKey="Gautier G" first="Gaëlle" last="Gautier">Gaëlle Gautier</name><affiliation wicri:level="1"><mods:affiliation>Chelatec SAS, 1 rue Aronnax, 44821, Saint‐Herblain Cedex, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Chelatec SAS, 1 rue Aronnax, 44821, Saint‐Herblain Cedex</wicri:regionArea></affiliation></author><author><name sortKey="Le Gal, Julien" sort="Le Gal, Julien" uniqKey="Le Gal J" first="Julien" last="Le Gal">Julien Le Gal</name><affiliation wicri:level="1"><mods:affiliation>Chelatec SAS, 1 rue Aronnax, 44821, Saint‐Herblain Cedex, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Chelatec SAS, 1 rue Aronnax, 44821, Saint‐Herblain Cedex</wicri:regionArea></affiliation></author><author><name sortKey="Martin, Thomas" sort="Martin, Thomas" uniqKey="Martin T" first="Thomas" last="Martin">Thomas Martin</name><affiliation wicri:level="2"><mods:affiliation>Covance Laboratories Ltd., Otley Road, HG3 1PY, Harrogate, England</mods:affiliation><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>Covance Laboratories Ltd., Otley Road, HG3 1PY, Harrogate</wicri:cityArea></affiliation></author><author><name sortKey="Kuper, Frieke" sort="Kuper, Frieke" uniqKey="Kuper F" first="Frieke" last="Kuper">Frieke Kuper</name><affiliation wicri:level="1"><mods:affiliation>TNO, Utrechtseweg 48, AJ, NL‐3700, Zeist, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>TNO, Utrechtseweg 48, AJ, NL‐3700, Zeist</wicri:regionArea></affiliation></author><author><name sortKey="Destexhe, Eric" sort="Destexhe, Eric" uniqKey="Destexhe E" first="Eric" last="Destexhe">Eric Destexhe</name><affiliation wicri:level="1"><mods:affiliation>GSK Vaccines, Rue de l'Institut 89, 1330, Rixensart, Belgium</mods:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>GSK Vaccines, Rue de l'Institut 89, 1330, Rixensart</wicri:regionArea></affiliation></author><author><name sortKey="Didierlaurent, Arnaud M" sort="Didierlaurent, Arnaud M" uniqKey="Didierlaurent A" first="Arnaud M." last="Didierlaurent">Arnaud M. Didierlaurent</name><affiliation wicri:level="1"><mods:affiliation>GSK Vaccines, Rue de l'Institut 89, 1330, Rixensart, Belgium</mods:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>GSK Vaccines, Rue de l'Institut 89, 1330, Rixensart</wicri:regionArea></affiliation><affiliation><mods:affiliation>Correspondence to: to. Lawrence Segal, GSK Vaccines, Rue Fleming 20, 1300 Wavre, Belgium. E‐mail: Arnaud Didierlaurent, GSK Vaccines, Rue de l'Institut 89, 1330 Rixensart, Belgium.E‐mail:</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: lawrence.m.segal@gsk.comarnaud.x.didierlaurent@gsk.com</mods:affiliation></affiliation></author><author><name sortKey="Garcon, Nathalie" sort="Garcon, Nathalie" uniqKey="Garcon N" first="Nathalie" last="Garçon">Nathalie Garçon</name><affiliation wicri:level="1"><mods:affiliation>GSK Vaccines, Rue de l'Institut 89, 1330, Rixensart, Belgium</mods:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>GSK Vaccines, Rue de l'Institut 89, 1330, Rixensart</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Applied Toxicology</title><title level="j" type="alt">JOURNAL OF APPLIED TOXICOLOGY</title><idno type="ISSN">0260-437X</idno><idno type="eISSN">1099-1263</idno><imprint><biblScope unit="vol">35</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1564">1564</biblScope><biblScope unit="page" to="1576">1576</biblScope><biblScope unit="page-count">13</biblScope><date type="published" when="2015-12">2015-12</date></imprint><idno type="ISSN">0260-437X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0260-437X</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Pandemic‐influenza vaccines containing split‐inactivated‐virus antigen have been formulated with the immunostimulatory Adjuvant System AS03 to enhance the antigen immunogenicity and reduce antigen content per dose. AS03 is an oil‐in‐water emulsion containing α‐tocopherol, squalene and polysorbate 80. To support the clinical development of AS03‐adjuvanted pandemic‐influenza vaccines, the local and systemic toxicity of test articles containing split‐influenza A(H5N1) and/or AS03 were evaluated after 3–4 intramuscular (i.m.) injections in rabbits. Treatment‐related effects were restricted to mild inflammatory responses and were induced primarily by the test articles containing AS03. The injection‐site inflammation was mild at 3 days, and minimal at 4 weeks after the last injection; and was reflected by signs of activation in the draining lymph nodes and by systemic effects in the blood including a transient increase of neutrophils. In addition, a study in mice explored the biodistribution of A(H5N1) vaccines or AS03 through radiolabelling the antigen or constituents of AS03 prior to injection. In this evaluation, 57–73% of AS03's principal constituents had cleared from the injection site 3 days after injection, and their different clearance kinetics were suggestive of AS03's dissociation. All these AS03 constituents entered into the draining lymph nodes within 30 min after injection. In conclusion, the administration of repeated doses of the H5N1/AS03 vaccine was well tolerated in the rabbit, and was primarily associated with transient mild inflammation at the injection site and draining lymph nodes. The biodistribution kinetics of AS03 constituents in the mouse were consistent with AS03 inducing this pattern of inflammation. Copyright © 2015 John Wiley & Sons, Ltd.</div><div type="abstract">To support the clinical development of candidate AS03‐adjuvanted pandemic‐influenza vaccines, local and systemic toxicity of 3–4 intramuscular (i.m.) injections of AS03, or AS03‐adjuvanted or unadjuvanted split‐A(H5N1) vaccines was evaluated in rabbits. The biodistribution of split‐A(H5N1) vaccines and the constituents of AS03 was explored in mice. All test articles were well tolerated. Treatment‐related effects were primarily associated with AS03 and were indicative of a transient mild local inflammation. The biodistribution kinetics of AS03 constituents were consistent with AS03 inducing this inflammation.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002194 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 002194 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:DBE0ACE0CB1C383C471B072CC5D1B71DD762A2FB
|texte= Non‐clinical safety and biodistribution of AS03‐adjuvanted inactivated pandemic influenza vaccines
}}
| This area was generated with Dilib version V0.6.34. |  |